Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
120 studies found for:    Melanoma (women OR woman OR female)
Show Display Options
RSS Create an RSS feed from your search for:
Melanoma (women OR woman OR female)
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Illness Related Distress in Women With Clinically Localized Cutaneous Melanoma
Condition: Melanoma
Intervention: Behavioral: questionnaire on-line or if uncomfortable with a computer interface, paper copies will be provided
2 Completed NIR-Guided Sentinel Lymph Node Mapping in Melanoma
Condition: Melanoma
Intervention: Procedure: Sentinel Lymph Node Mapping
3 Recruiting Yervoy Pregnancy Surveillance Study
Condition: Melanoma
Intervention: Drug: Yervoy
4 Completed Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Vinorelbine;   Drug: Docetaxel;   Drug: Sargramostim
5 Recruiting A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma
Conditions: Advanced Melanoma;   Metastatic Melanoma
Intervention:
6 Recruiting Teaching Skin Self -Examination to Melanoma Patients and Their Skin Check Partners
Condition: Melanoma
Intervention: Behavioral: Skin Self- examination structured training
7 Recruiting Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)
Conditions: Malignant Melanoma;   Metastases
Intervention: Drug: Buparlisib
8 Completed
Has Results
Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study
Condition: Metastatic Malignant Melanoma
Interventions: Drug: Avastin;   Drug: Abraxane
9 Recruiting Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Biological: DC vaccine;   Drug: Dasatinib
10 Terminated Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma
Condition: Melanoma
Intervention:
11 Recruiting A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Condition: Melanoma
Interventions: Biological: Poly-ICLC;   Biological: Peptides
12 Completed Disulfiram in Patients With Metastatic Melanoma
Condition: Stage IV Melanoma
Intervention: Drug: Disulfiram (DSF)
13 Recruiting Dendritic Cell Activating Scaffold in Melanoma
Condition: Melanoma
Intervention: Biological: WDVAX
14 Completed Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: polarized dendritic cells;   Biological: non-polarized dendritic cells
15 Unknown  Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma
Condition: Metastatic Melanoma
Intervention: Drug: Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.
16 Recruiting Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
Conditions: Metastatic Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Dabrafenib;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Trametinib
17 Active, not recruiting Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF)
Condition: Melanoma
Intervention: Biological: Autologous, lethally irradiated melanoma cells
18 Active, not recruiting Panobinostat (LBH589) in Patients With Metastatic Melanoma
Conditions: Melanoma;   Malignant Melanoma
Intervention: Drug: LBH589
19 Completed GM-CSF in Women With Recurrent Ovary Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer
Intervention: Drug: GM-CSF, Leukine
20 Suspended Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: Leflunomide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.